Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

y income increased 34%, or $59,017 to $230,789 in the three months ended June 30, 2009, compared to $171,772 for the first quarter of 2009. This increase is a result of higher sales activities of our nutritional products by Perrigo. Royalty payments are based on Perrigo's net profits from the sale of CDT-based products which involve uncertainties and are difficult to predict.

Total revenues decreased 26%, or $142,565 to $402,561 for the six months ended June 30, 2009, compared to $545,126 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo.

Marketing and selling expenses decreased 79%, or $151,579 to $39,468 for the three months ended June 30, 2009, compared to $191,047 for the same period in 2008 and decreased 66%, or $282,688 to $146,051 for the six months ended June 30, 2009, compared to $428,739 for the same period in 2008. These decreases are due to a reduction in personnel related expenses due to reduction in personnel and lower advertising and tradeshow expenses. In addition, commission expense decreased due to lower royalty income.

Research and development expenses decreased 34%, or $403,818 to $793,503 for the three months ended June 30, 2009, compared to $1.2 million for the same period in 2008 and decreased 22%, or $465,096 to $1.6 million for the six months ended June 30, 2009, compared to $2.1 million for the same period in 2008. These decreases were primarily due to our decision to defer development activities on certain projects pending additional funding and a reduction in personnel related expenses due to personnel reductions. These decreases were offset by an expense related to settlement of claims by a former employee.

General and administrative expenses decreased 8%, or $89,762 to $972,884 for the three months ended June 30, 2009, compared to $1.1 million for the same period in 2008 and decreased 7%, o
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... (PRWEB) September 16, 2014 “Nature has ... the features that we desire in optical design,” said ... Montana State University. “As we explore surfaces and structures ... those lessons were presented in San Diego in August ... Light in Nature ” chaired by Shaw and Rongguang ...
(Date:9/16/2014)... 2014 --The emerging field of molecular electronics could ... level, enabling the construction of tiny circuits from ... molecules would take on the roles currently played ... team of researchers from five Japanese and Taiwanese ... in small-scale electronics: a molecule called picene. In ...
(Date:9/16/2014)... , Sept. 16, 2014 Cardioxyl Pharmaceuticals, ... compound has been shown to be effective in animal ... an alternative to intravenous infusions that could pave the ... data were presented yesterday at the Heart Failure Society ... in Las Vegas . ...
(Date:9/16/2014)... 2014   Synthetic Biologics, Inc. (NYSE ... biologic and drug programs targeting specific pathogens that ... of the Company,s Investor Day in ... bowel syndrome (IBS) program, including its novel, oral ... In the keynote presentation, Mark Pimentel , ...
Breaking Biology Technology:Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... , , , , , ... that can be applied to all PCR amplifications. For example, , ... of the PCRs can differ from each other. Finding the optimal ... for reliable results , and efficient amplification of a specific ...
... , , , , , , ... University Hospital and Medical School of the Dutch-speaking Brussels Free , ... , , , , , ... , Preimplantation diagnosis (PGD) is a very early form ...
... , , , , ... Behrens, PhD, and Dietmar Kahle, PhD , ... Dept., Bernhard-Nocht-Str. 74, D-20359 Hamburg , ... Am Botanischen Garten, D-24118 Kiel , Barbara ...
Cached Biology Technology:PCR Optimization 2PCR Optimization 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 2The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 3The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 4The use of the Mastercycler gradient for single-cell PCR and preimplantation , diagnosis 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 2Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 3Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 4Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 5Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 6Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 7Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 8Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 9Optimizing DNA Amplification Protocols using the Eppendorf Mastercycler 10
(Date:9/16/2014)... American Menopause Society (NAMS) has published its key, ... womenon everything from hot flashes to heart disease. ... Recommendations for Clinical Care of Midlife Women," was ... Menopause . This is the first, comprehensive set ... women freely available to all clinicians who care ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... species has its own bacterial identity. That,s the conclusion ... institutions who studied the genetic fingerprints of bacteria on ... , "This study demonstrates for the first time that ... ecological strategies possess very different microbial communities on their ... postdoctoral researcher in the UO,s Institute of Ecology and ...
Breaking Biology News(10 mins):Microbiome research shows each tree species has a unique bacterial identity 2
... Motion, Matches with Watch-list Databases and Reports ... Neurotechnology, a provider of high-precision biometric ... VeriLook Surveillance SDK, a software development kit ... streams from high-resolution digital surveillance cameras. Unlike ...
... March 10 CEL-SCI Corporation (NYSE Alternext US: CVM) ... a new manufacturing process that could allow drugs developed ... their potency and thereby potentially also their shelf life. ... CEL-SCI may also significantly accelerate the time to market ...
... results March 19 during 12 p.m. Advertising Research ... Research (R), a revolutionary media research firm, recently ... Research Foundation (ARF) conference and provided attendees with ... that comprise impactful presentations. Results of the study, ...
Cached Biology News:VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 2VeriLook Surveillance SDK Provides Real-Time Face Identification Using Video Surveillance Cameras 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 2CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 3CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products 4Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations 2
The mini vertical flow workbench is designed to perform PCR protocols in a particle-free environment. The built-in UV light ensures the elimination of any nucleic acid to avoid cross-contamination....
... SuperScript™ II RNase H- Reverse Transcriptase ... SuperScript™ RNase H- RT. It is a ... strand from single-stranded RNA DNA or an ... by the introduction of point mutations rather ...
... Array CGH Genomic Labeling Systems are a ... of genomic DNA samples for array-based Comparative ... and direct labeling formats, the BioPrime Plus ... flexible solution to your genomic labeling needs. ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: